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A	large	population	of	possible	different	Nano-objects	
	
H0:	Nano	is	not	Efficient	
H1:	Nano	is	Efficient	
H0:	Nano	is	not	Toxic	
H1:	Nano	is	Toxic	
SAFETY:	EFFICACY:	
Prob[Efficacy|Data]	?		 Prob[Safety|Data]	?		
How	to	minimize	the	risks	of	bad	decisions	?	
Quality-by-Design	:	an	approach	to	estimate	and	control	those	risks	
ICH	Q8,Q9,Q10		
Risk	Management	
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Systems	
Engineering	
QibD	
Genesis	 GMP	 cGMP	
QbD		
(ICH	Q8)	
Extensions	
>	1980	 >	1990	 2002	 2004	 >	2005	
Historical	background	
•  Aeronautics	&	Automative	Industries	:	Total	Quality	Management,	Design	for	Six-Sigma		
•  FDA	officials	realized	that	biologics	and	drugs	could	also	stand	to	benefit	from	QbD.	
•  Concept	paper	on	21st	Century	Good	Manufacturing	Practices.	
•  FDA	produced	a	guidance	document	:		«	Pharmaceutical	cGMPs	for	the	21st	Century	»	
•  ICH	published	the	Guideline	document:	Q8	(R2):	Pharmaceutical	Development.	
•  Now	adaptation	for	Biomedical	Devices	&	Analytical	Methods*	
*S.	Chatterjee,	QbD	Considerations	for	Analytical	Methods	-	FDA	Perspective,	IFPAC	Annual	Meeting,	Baltimore,	Jan	2013		
3	
QbD	LifeCycle	
A	risk-based	project	management	:	
	
•  6	main	tasks	
•  6	main	deliverables	
•  4	go	/	no	go	tests	
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QbD-1:	Profile	your	Nano	
QTPP	
Quality	Target	Product	Profile	
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ü  Pharmacokinetics		
ü  Clinical	Intended	Use		
ü  Reference	Listed	Drug		
ü  Scale	Of	Production		
ü  Safety	Concerns		
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QbD-2:	Quality	Attributes	?	
Critical	Quality	Attributes	?		
To	measure	potential	consequences	we	need	to	
define	relevant	QA		QA	=	physico-chemical	or	
biological	property	to	be	controlled	to	ensure	to	get	
the	expected	quality/safety/efficacy	requirement.	
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QbD-3:	Formulation	&	Production	Factors	?	
24 BioProcess International JUNE 2010
a minimum number of experiments 
varying all operating parameters 
simultaneously 
experiments, operators, raw materials, 
or processes themselves 
process parameters, unlike with one-
factor-at-a-time experiments 
key and critical process parameters 
contributing to identification of a 
design space, which helps to provide 
an “assurance of quality.” 
Proper execution of DoE within a 
design space is safe under QbD in 
bioprocess industries because work 
within a design space is not considered 
a change (1). However, some pitfalls 
can lead to a poorly defined design 
space. They can come from 
unexpected results, failure to take 
account of variability (due to assay, 
operator, or raw material) within a 
process, and the choice of parameters 
and their ranges considered in an 
experimental study, as well as errors in 
statistical analysis (e.g., model 
selection, residual analysis, 
transformation of response). We 
present here some good industrial 
practices based on our experience, on 
literature for the application of a DoE 
approach in bioprocess industries, and 
on nonbiotechnological industrial 
approaches (e.g., the oil and chemical 
industries, in which DoE and similar 
statistical techniques have been 
applied for many years). 
Setting “SMART” Objectives: It is 
always important before beginning 
experimentation to determine the 
objective of an experiment, and this is 
no different with DoE. Identifying 
objectives helps focus a team on its 
specific aims (scientific understanding 
of the task/problem in hand) over a 
period of time. It also helps indicate 
what resources are and assists in 
managing expectations from a study’s 
outcome (4). DoE studies in support of 
QbD are often a delicate balance 
between delivering defined, high-
quality products and meeting 
predetermined time, labor, and 
financial constraints (5). Consequently, 
Figure 1: Typical bioprocess with a complicated nest of parameters influencing the final drug product 
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Process Stage
Ri
sk
 P
rio
rit
y 
N
um
be
r (
RP
N
)
Parameters
with high RPN 
scores (high
risk parameters)
need further
investigation
Parameters with
low RPN scores
(low risk
parameters)
Inoculum
Se
ed
 Fe
rm
en
to
r
Pro
du
cti
on
Fe
rm
en
to
r
Se
pa
rat
ion Refold
Co
lum
n #
1
Co
lum
n #
2
Di
afi
ltr
ati
on
Fil
tra
tio
n
Figure 3: Cause-and-effect (fishbone) diagram  
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Which	are	the	most	influent	factors	that	
could	cause	variability	of	CQA	?	
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QbD-4:	Design	Space	?	
CQA	=	f(CMA,CPP)	
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QbD-5:	Control	Strategy	?	
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QbD-6:		Product	LifeCycle	Management	 ProjectStart
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In	Practice	?	
12	
In	practice	?	
T.	Bastogne,	“Quality-by-design	of	nano-
pharmaceuticals	-	A	state	of	the	art,”		
Nanomedicine:	Nanotechnology,	Biology,	and	
Medicine.	June	2017.	
•  Bibliographic	engine:	Web	of	Science	
•  Keywords:	nano,	quality-by-design	&	drug	delivery	
•  Replication:	every	6	months	
•  30	identified	articles	between	2007	and	2017		
0	
1	
2	
3	
4	
5	
6	
7	
8	
9	
2007	 2008	 2009	 2010	 2011	 2012	 2013	 2014	 2015	 2016	
QdD	Articles	in	Nanomedicine	
This	work	was	supported	by	the	European	Union	and	the	ERA-NET	framework	under	the	EuroNanoMed	II	project	NanoBiT.	
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Where	in	practice	?	
1.  Asia	(44%)	
2.  USA	(28%)	
3.  Europ	(15%)	
4.  Africa	&	Middle	East	(13%)	
Asia	
USA	
EU	
Middle	East	
Africa	
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1)	QTPP	
•  Frequency:	5/30	(16.7%)	
•  Since	2015	
	
Shirsat and Chitlange: Optimization of rizatriptan loaded chitosan nanoparticles: QbD approach
89Journal of  Advanced Pharmaceutical Technology & Research | Jul-Sep 2015 | Vol 6 | Issue 3
Chitosan is nontoxic, biodegradable, biocompatible, 
hydrophilic, and it has antibacterial activity, protein 
affinity, positive polyanions and also approved as GRAS 
by the USFDA. Furthermore, it has been reported that the 
bioavailability of drug, proteins, and vaccines was raised 
by opening the tight junctions of epithelial cell layers and 
increasing the retention time of drug delivery locally using 
CS as polymer.[7,10-12] Ionic gelation method involves ionic 
cross-linking of amino groups of CS and phosphate groups 
of tripolyphosphate (TPP), to form spontaneous gelation in 
aqueous solution.[13,14] Many properties of CS nanoparticles 
such as surface morphology, entrapment, and release 
characteristics are highly related to formulation and process 
parameters, such as concentration and molecular weight 
of CS, pH and concentration of cross-linker agent, curing 
time, stirring time, and speed.[7,15] Quality by design (QbD) 
approach can be applied for better understanding of the 
process and formulation variables, which can lead to better 
and robust quality into the product assuring the target 
quality product profile. Based on risk assessment of process 
and formulation variables, design of experimentation (DoE) 
study need to conduct on critical parameters to establish 
certain ranges for critical parameters within certain range 
to obtain design space (DS).[16-20]
In present study, we aimed to develop RZT CS nanoparticles 
formulation using QbD approach to understand the effect 
of process and formulation variables on critical quality 
attributes (CQAs) of RZT CS nanoparticles and to establish 
DS with accepted Quality Target Product Profile (QTPP).
MATERIALS AND METHODS
Rizatriptan, CS was supplied as gift sample from Cipla 
Ltd. (Mumbai, India) and Central Institute of Fisheries 
Technology, Cochin, India (medium molecular weight, 95% 
deacetylated) respectively. All other excipients, solvents 
were of pharmaceutical and analytical grade.
Formulation of rizatriptan chitosan nanoparticles
Nanoparticles were prepared using modified ionic gelation 
method,[21,22] where CS was dissolved in 1% acetic acid 
solution to a various concentration and TPP was dissolved 
in distilled water with various concentrations, based 
on the results of preliminary study. RZT was uniformly 
dispersed in TPP solution and this solution was added 
drop-wise to CS solution under continuous stirring at 
room temperature. RZT CS nanoparticles formed based on 
the principle of electrostatic attraction between positively 
charged primary amino groups on CS chains and charged 
polyanions (TPP). RZT CS nanoparticles were centrifuged 
at 6000 rpm for 30 min (Remi R-88). The supernatant liquid 
was separated and nanoparticles were redispersed in PBS 
at pH 6.8 and ultrasonicated for 5 min to disaggregate the 
CS nanoparticles. Three nanoparticles optimized batches, 
were redispersed in deionized water containing 1% w/v 
mannitol as cryoprotectant, and lyophilized primarily for 
12 h at −20°C and secondary for 36 h at − 54°C with vacuum 
pressure of 0.001 mbar using Christ freeze-dryer (Christ 
Alpha 1-2 LD). Nanoparticles were collected, kept in glass 
vials and stored in dessicator.
Optimization of rizatriptan chitosan nanoparticles
The QTPP is an essential element of a QbD approach and 
forms the basis of design of the product. QTPP for RZT CS 
nanoparticles were presented in Table 1 considering the 
formulation and process to develop nanoparticles.
Risk assessment
Initial risk assessment of process parameters and formulation 
components of RZT CS nanoparticles was performed to 
identify critical parameters and components having a 
high-risk of impacting the drug product CQAs. High-risk 
parameters to the CQAs of RZT CS nanoparticles were 
further evaluated by performing experiments as per the 
DoE to reduce the risk.
Optimization using central composite design
Based on risk assessment and preliminary studies, 
optimization of three high-risk parameters at more than 
3 levels needed to identify main and interaction effect of 
selected parameters on responses with minimum number 
of runs. Central composite design (CCD) was selected for 
RZT CS nanoparticles with % CS (X1), % TPP (X2), and 
stirring speed (X3) at 3 levels and 2 more levels as star points 
(−α, +α) was selected as shown in Table 2. The obtained RZT 
CS nanoparticles suspensions were further evaluated for 
particle size, entrapment efficiency.
Optimization of design space and validation of model
Design space was generated by setting acceptance criteria 
to CQAs. The 3 optimization formulations were prepared 
within DS and compared with predicted results of the 
responses and percentage error was calculated to validate 
the selected model.
Table 1: QTPP for RZT CS nanoparticles
Profile component Target Justification
Dosage form Nanoparticles Novel dosage form for 
targeted drug delivery
Dosage design Sustained release 
nanoparticles
For long-term 
treatment of RZT
Particle size (nm) 350-650 Narrow distribution
Entrapment 
efficiency (%)
>50 Higher entrapment 
is better for the 
nanoparticulate 
dosage form
Drug release (h) >48 To achieve sustained 
drug release for long 
period of time
RZT: Rizatriptan, QTPP: Quality target product profile, CS: Chitosan
[Downloaded free from http://www.japtr.org on Monday, September 05, 2016, IP: 80.215.3.68]
A.E.	Shirsat	&	S.S.	Chitlange,	2015	
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Table 2 QTPP and CQA of target drug product, gel with polymeric nanoemulsified particles, for injection
QTPP of a gel with polymeric nanoemulsified p rticles
QTPP elements Target Justification
Dosage form Hydrogel Pharmaceutical equivalence requirement: same 
dosage form
Route of administration Injection Pharmaceutical equivalence requirement: same 
route of administration
Dosage strength % of drug substance (% w/w) Pharmaceutical equivalence requirement: same 
dosage strength
Dosage form design Polymeric nanoemulsified carriers incorporated 
into hydrogel
Match reference-listed drug product
Pharmacokinetics Bioequivalent to reference-listed drug Match reference-listed drug product
Stability Shelf life not 24 months at room temperature Equivalent or longer shelf life compared to 
reference-listed drug product
Drug product quality attributes Physical attributes, identification, assay, 
uniformity of content, degradation products, 
residual solvents, dissolution, microbiological 
quality, pH, and rheological behavior
Pharmaceutical equivalence requirement: fulfill the 
same quality standards as reference-listed drug 
product
Container closure system Suitable container closure system that will 
support estimated shelf life and drug product 
integrity during the transport, Identical primary 
packaging as reference-listed drug product
Vials or prefilled syringes, similar with reference-
listed drug product, acceptable for the patient
Alternative methods of administration No None are listed on reference drug product labeling
CQAs of gel with polymeric nanoemulsified particles
Drug product quality attributes Target Is it a CQA? Justification
Physical attributes
Appearance Color and shape acceptable 
for the patient
No Color and shape are not directly related to the safety and 
efficacy. Required for patient acceptability
Particle size and particle size 
distribution
Similar to reference-listed 
drug
Yes It might influence drug entrapment efficacy and capacity, as well 
as drug release. It is critical for drug product efficacy and safety
Rheological behavior Conform to Ph. Eur. 
7.0–2.2.10
Yes Required to demonstrate Q3 (same components in same 
concentrations with same microstructure)
pH Conform to Ph. Eur. 
7.0–2.2.3
Yes Might influence drug product stability and hence its efficacy 
and safety. This CQA can be effectively controlled by quality 
management system
Identification Positive for drug substance Yes Identification is critical for safety and efficacy, but this CQA can 
be efficiently controlled by quality management system and will 
be followed during dissolution studies. Formulation and process 
variables cannot influence identity
Assay 90%–110% of label claim Yes Assay variability will have influence upon safety and efficacy
Content uniformity Conform to USP 3 Yes Variability in content homogeneity and uniformity of content will 
affect safety and efficacy
Residual solvents Conform to ICH Q3C (R5) Yes Polymeric nanoemulsified particles manufacturing procedure 
includes use of methanol. Its residual quantity is critical for safety
Degradation products Conform to ICH Q3B (R2) Yes Degradation products limit is critical for safety. Limit of individual 
unknown degradation products must comply with ICH Q3B (R2). 
Limit of total degradation products is based on reference-listed 
drug product analysis near the expiry date
In vitro dissolution profile Match reference-listed drug 
product
Yes As the in vitro drug release is surrogate for in vivo performance, 
the target is to ensure similar dissolution profile compared to 
reference-listed drug product (f2 50)
Microbiological quality Conform to Ph. Eur. 
7.0–5.1.4
Yes Noncompliance of microbiological quality will have impact upon 
safety
Preservative content 80%–110% from label claim Yes Required to ensure antimicrobial effectiveness
Efficacy of antimicrobial preservation Conform to Ph. Eur. 
7.0–5.1.3
Yes Inefficiency of the preservative at declared storage conditions 
might result in microbiological contamination and affect safety
Container closure system Similar to reference-listed 
drug
No Match reference-listed drug product. Required for patient 
acceptability
Packaging integrity No failure No Required for stability, efficacy, and safety
Note: Q3, the US Food and Drug Administration similarity definition of the generic drug had the same components in the same concentration with the same arrangement 
of matter (microstructure) as the reference-listed drug. 
Abbreviations: QTPP, quality target product profile; CQAs, critical quality attributes; Ph. Eur., European Pharmacopoeia; USP, United States Pharmacopeia; ICH, 
International Conference on Harmonization guidelines.
A.S.	Zidan,	2016	
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2)	CQA	Specification	
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e5	main	Critical	Quality	Attributes	(70%)	
	
1.  NP	Size	
2.  Encapsulation	Efficiency	
3.  Polydispersity	Index	
4.  Zeta	Potential	
5.  Amount	of	Release	
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3)	CMA	Specification	
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6	Criticial	Material	Attributes	>	90%	
	
1.  Ingredient	Concentration	
2.  Ingredients	Ratio	
3.  Drug	Load	
4.  Surfactant	Concentration	
5.  Ingredient	Type	
6.  Surfactant	Type	
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4)	CPP	Specification	
•  No	really	dominant	CPP	
•  Process	dependant	
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5)	Prior	Risk	Analysis	
•  Frequency:	5/30	(16.7%)	
•  Since	2015	
	
2.5. Quality target product profile (QTPP) and risk analysis of RHT SLN
The QTPP is described as the quality properties that a drug pro-
duct need to possess so as to fulfill the objectives set in target pro-
duct profile as quantitative attributes. QTPP should furnish a
quantitative surrogate to describe the aspects of clinical safety
and efficacy by determining the CQA, CPP and control strategy
(ICH, 2009).
In case of RHT SLN, QTPP is a lower size and PDI with lipidic core
is expected to facilitate transport of drug across the nasal mucosal
barriers both into the cerebral tissues and systemic circulation.
Lower PDI is to reduce aggregation of particle during long term sta-
bility. Higher entrapment efficiency is to achieve higher drug load-
ing in lipid matrix (Vora et al., 2013). The crucial step in risk
assessment is to gather the entire responsible factor systematically
that could influence the desired product quality. These factors
were categorized hierarchically using an Ishikawa diagram
(Fig.1). The parameters summarized in Ishikawa diagram assisted
in the identification of failure modes of SLN formulation.
2.6. Preliminary screening of lipid, stabilizer and HSH rpm
In DOE, preliminary screening is a crucial step for the selection
of CPP which affects CQA like size, PDI and % entrapment efficiency
(%EE) of developed SLN. Preliminary screening of lipid, stabilizer
and HSH rpm was carried out so as to obtain SLN of smaller size,
narrow PDI and higher %EE. Based on solubility study, D: L and
lipids were screened for optimization of final lipid. Further these
lipids were taken and different batches of RHT SLN as shown in
Table 2 were prepared by method described in Section 2.4 using
tween 80 (2% w/w) as surfactant and HSH at 10000 rpm for
homogenization time (HT) 10 min without probe sonication. To
screen out lipid Batch nos. 1–3 (Table 2) were characterized for
size, PDI and %EE. After selection of final lipid, D: L, HSH rpm and
time were kept constant and the effect of stabilizer on CQA was
verified by formulating RHT SLN using surfactant alone (2% w/w
tween 80, Batch no. 3, Table 2) and combination of surfactant with
stabilizer (Batch no. 4 and 5, Table 2). Subsequently the effect of
higher HSH rpm (Batch no. 6) on CQA was determined as shown
in Table 2.
2.7. 33 factorial design
Based on preliminary experimental data, 33 factorial design was
selected for the optimization of RHT SLN where the effect of three
independent variables or CPP viz., D: L (X1), surfactant concentra-
tion (X2) and HSH time (X3) on CQA (Y1 = size, Y2 = PDI and
Y3 = %EE) was determined at three different levels (Table 3 and
4). Compritol, tween 80 and Pol-188 were selected as lipid, surfac-
tant and stabilizer respectively. HSH rpm (10000) and Pol-188 con-
centration (1% w/w) were set as fix levels.
33 Factorial design was analyzed using Design expert software
(Version 8, Stat-ease. Inc, USA) and the polynomial equation was
derived. The magnitude of coefficients in polynomial equation
have either positive sign, indicating synergistic effect or negative
sign, indicating antagonistic effect. Best fitting experimental model
(linear, two factor interaction, quadratic and cubic model) was
taken statistically on the basis of comparison of several statistical
parameters like coefficient of variation (CV), multiple correlation
coefficient (R2), adjusted multiple correlation coefficient (adjusted
R2), predicted residual sum of square and graphically by 3D
response surface plot provided by Design Expert software. The
level of significance was considered at p-value < 0.05. The regres-
sion analysis, linear regression plots (observed versus predicted
value) and Pareto chart of the dependent variables were plotted
using MS-Excel.
2.8. Data optimization and model validation
The effect of each independent CPP on CQA was analyzed for
establishment of design space with the target of ensuring desired
product quality. Hence, 33 factorial design was applied for estab-
lishment of design space to investigate the responses of process
parameters on quality attributes of RHT SLN. The optimization
was done on the basis of attaining lower particle size, PDI and
higher %EE using overlay plot (graphical) and desirability (numer-
ical) criteria. In order to establish the reliability of developed
model, check-point analysis was performed by taking two valida-
tion batches viz., V1 and V2 (Table 4) whereby magnitude of error
between observed and predicted values was evaluated.
2.9. Effect of probe sonication on optimized RHT SLN
It is often sonication which brings about further reduction in
size with narrow PDI. Sonication breaks coarse drops into nano
droplets and hence, it is responsible in obtaining smaller particle
size of SLN (Das et al., 2011). To evaluate the effect of probe soni-
cation on size, PDI and %EE of RHT SLN, different trials were taken
by varying amplitude and sonication time as shown in Table 5. The
final optimized formula with composition of RHT SLN is shown in
Fig.2.
2.10. Characterization of RHT SLN
For characterization, three batches of optimized RHT SLN were
formulated and they were characterized for physicochemical, mor-
phological, diffusion and histopathological parameters as shown
below.
2.10.1. Particle size, PDI and Zeta Potential
Particle size, PDI and zeta potential measurements were per-
formed by photon correlation spectroscopy using Zetasizer
(Nano-ZS90, Malvern, Worcestershire, UK). Before measuring size,
Table 1
Solubility study (n = 3).
Lipids Melting point (!C) Drug: lipid ratio
(D: L)
1:2 1:3
Apifil 62–65 + ++
Compritol 65–77 ++ +++
GMS 55–60 ++ +++
PA 52–55 ++ +++
Stearic acid 69–70 + ++
+ Not clear, ++ Turbid, +++ Clear.
Fig. 1. Ishikawa diagram illustrating CPP affecting on CQA of RHT SLN.
56 B. Shah, D. Khunt, H. Bhatt et al. / European Journal of Pharmaceutical Sciences 78 (2015) 54–66
B.	Shah	et	al.,2015	
2.2.4. Pseudoternary phase diagram
Pseudoternary phase diagram was used to determine the
concentration of lipid, surfactant, water, on the border line of ME
region for the preparation of microemulsion (ME) (Fadda et al.,
2013; Garg et al., 2016a). The lipid phase was heated to melt the
solid lipid, which is mixed with heated phospholipid ethanolic
solution mainly at the temperature of 55–60 !C. The lipid pha e
and the surfactant phase (Smix) were heated simultaneously at the
similar temperature i.e., 60 !C. At this temperature, a series of
continuous known amount of Smix and lipid were taken and
simultaneously titrated with aqueous phase and vice-versa with
the help of micro-syringe. After each addition, mixture was gently
stirred and then placed in a temperatu  controlled water bath.
Titration was continued until the turbidity appears in the sample,
weight percent of each (individual) components used in the
titration was calculated, and plotted in Gibbs phase triangle as
boundary points. The entire phase diagram was mapped in this
manner by oil titration too (i.e., where oil acts as titrant).
2.2.5. Preparation of ACE-loaded NLCs
NLCs were prepared by ME method, by selecting the net
composition of ME region obtained by the Pseudoternary phase
diagram (Garg et al., 2016a). Lipid phase consisted of cetyl alcohol
as solid lipid, Transcutol1P as liquid lipid (oil) and aqueous phase
consists of water containing tween 80. Phospholipid (PL) was
dissolved in ethanol and ACE was dissolved in Transcutol1P. In the
procedure, CA was mixed with ethanolic solution of PL and heated
to 55–60 !C followed by addition of heated lipid oil (Transcutol1P).
After proper mixing of hot lipid phase, hot water (heated at the
same temperature) was added into lipid mixture. At this stage,
primary ME was formed. After stirring for 5 min, the above mixture
was added to 0.5% w/w poloxamer solution under continuous
homogenization. Homogenization was carried out at 8000 rpm for
15 min using high shear homogenizer (Heidolph, Germany), and
the mixing was done by magnetic stirring (Remi, Mumbai, India)
for 2–3 h at 500 rpm.
2.2.6. Systematic FbD optimization of ACE-NLCs as per the
experimental design
Diverse response variables were optimized using a 33 Box-
Behnken Design (BBD). In this, the amount of CFAs i.e., Solid lipid
(x1), Smix (X2) and liquid lipid (Lipid oil) (X3) were studied at the 3
different levels i.e., "1 (low), 0 (intermediate) and +1 (high), which
are equidistant from each other. The center points (i.e., 0, 0, 0) were
studied in quintuplicate. All other formulation and process
variables were fixed during the study. All the studied 17
experimental runs along their factor combinations are summa-
rized in Supporting information (Supplementary data Table 1)
(Singh et al., 2011). As per the design all the prepared formulations
were investigated for particle size (nm), entrapment efficiency (EE)
(%), release (%) and permeation flux (mg/cm2/h) as the response
variables.
2.2.6.1. QbD-based optimization data analysis and validation of
QbD. The prep red NLCs were evaluated for response variables
like particle size, % EE, % release and permeation flux, and
thereafter optimization data analysis was also carried out. Later,
second-order quadratic polynomial model was selected for
mathematical modeling to carried out in search of possibility of
significant interaction(s) in the studied responses (Bhatia et al.,
2013). The generated model from design was evaluated for various
parameters like coefficient of variation (CV), correlation coefficient
(R2), adjusted correlation coefficient (adjusted R2), and predicted
residual sum of square were compared. The significance level was
found to be highly significant (p < 0.05). The regression analysis,
linear regression plots (observed versus predicted value) and
Pareto chart of the dependent variables were plotted. The 3D-
response surface plots & 2D-contour plots were generated to carry
out the response surface analysis (RSA), which were obtained by
applying Design Expert1 version 10.0.
Finally, the numerical optimization method using desirability
function by “trading-off” of response variables (Garg et al., 2015a;
Negi et al., 2014) was c rried out for projection of optimum
formulation. The location of the optimized formulation in the
design space was marked with flag containing all the parameters of
the formulation. Along with the optimized formulation the
validation was also carried out by choosing 7 confirmatory
check-points from the defined design space region and were
assessed for various CQAs, by constructing linear esidual and
correlation plots betw en the pr dicted as well as observed
responses and the% prediction error was also calculated.
2.2.7. Characterization of NLCs
2.2.7.1. Size, polydispersity index (PDI) and zeta potential. The
p epared NLCs formulations were studied with respect to their
particle size, PDI and zeta potential by using Zetasizer Nano ZS90
(Malvern Instruments, UK). An aliquot of NLCs suspension was
diluted 10 times with distilled water. Samples were kept in
polystyrene cuvette and observed at a fixed angle of 90! at
25 # 0.1 !C. The zeta potential of NLCs was determined by laser
Doppler anemometry at 25 # 0.1 !C. The undiluted samples were
kept in the electrophoretic cell with an electric field of 15.24 V/cm.
2.2.7.2. Evaluation of surface morphology. The surface morphology
of the prepared NLCs was evaluated with the help of Scanning
Table 1
Initial risk assessment for ACE-NLCs.
High risk parameter, Medium risk parameter, Low risk pa ameter.
N.K. Garg et al. / International Journal of Pharmaceutics 517 (2017) 413–431 415
N.K.	Garg	et	al.,	2017	
Criticity	=	Severity	x	Frequency	
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4	mian	measurement	techno.	>	50%	
	
1.  Dyn.	Light	Scaterring	
2.  HPLC	
3.  Trans.	Electro.	Microscopy	
4.  X-Ray	Diffraction	
T	Bastogne,	JRC-Ispra	27-28	Sep	2017	 20	
Design	of	Experiments	
•  Many	inconsistencies	between	DoE	
methods	and	objectives	
•  A	good	software	is	necessary	but	not	
enough	!	Expertise	is	needed	
•  Confidence	of	the	results	requires	to	
apply	strictly	validation	procedures.	
•  Only	5/30	papers	have	really	
implemented	a	cross-validation	step	
Shirsat and Chitlange: Optimization of rizatriptan loaded chitosan nanoparticles: QbD approach
94 Journal of  Advanced Pharmaceutical Technology & Research | Jul-Sep 2015 | Vol 6 | Issue 3
at its melting point at 178–180°C revealing the crystalline 
nature. CS thermogram reveals the amorphous nature with 
a peak around 75–80°C. Physical mixture of RZT, CS, and 
TPP showed less intense peak at the melting point of drug, 
Table 6: Validation of design space of RZT CS nanoparticles
Formulation 
code
Composition (% w/v) Response Predicted 
value
Experimental 
value
SE
X1 CS X2 TPP
21 2.74 3.68 Y1 - Particle size 565.58 570.24 1.33
Y2 - Entrapment efficiency 62.08 63.14 1.03
22 3.30 2.83 Y1 - Particle size 422.42 437.21 2.62
Y2 - Entrapment efficiency 64.28 63.78 −0.75
23 2.96 3.17 Y1 - Particle size 479.16 491.24 3.29
Y2 - Entrapment efficiency 64.21 65.8 0.70
RZT: Rizatriptan, CS: Chitosan, TPP: Tripolyphosphate, SE: Standard error
Table 7: Accelerated stability results for RZT CS nanoparticles
Batch 
number
Entrapment efficiency* (% w/w) Particle size (nm) Zeta potential (mV) PDI
Initial 3 months Initial 3 months Initial 3 months Initial 3 months
21 99.57±2.4 96.54±1.59 570.24 584.14 +33.56 +32.68 0.247 0.226
22 101.52±2.3 98.14±2.45 437.21 448.75 +35.6 +34.81 0.256 0.216
23 99.75±2.61 96.57±2.74 491.24 496.97 +32.43 +31.98 0.128 0.142
*For entrapment efficiency of RZT loaded CS nanoparticles were weighed equivalent to RZT 25 mg. RZT: Rizatriptan, CS: Chitosan, PDI: Polydispersity index
Design-Expert® Software
Factor Coding: Actual
Overlay Plot
Particle Size
  CI Low
  CI High
Entrapment Efficiency
  CI Low
  CI High
Design Points
X1 = A: Chitosan
X2 = B: TPP
Actual Factor
C: Stirring Speed = 900.00 1.32 2.16 3 3.84 4.68
0.32
1.16
2.00
2.84
3.68
Overlay Plot
A: Chitosan (%)
B:
 T
PP
 (%
)
Particle Size: 350
Particle Size: 350
Particle Size CI:  350
Particle Size CI:  650
Entrapment Efficiency: 50
Entrapment Efficiency CI:  50
Entrapment Efficiency CI:  67.15
6
Figure 8: Design space for rizatriptan loaded chitosan nanoparticles
intensity as compared to pure drug might be due to 
matrix formation with polymer. This indicates that there 
was no any interaction of drug and polymer in RZT CS 
nanoparticles.
Scanning electron microscopy
Freeze – dried nanoparticles with mannitol as a 
cryoprotectant in powder formulation appears to be slightly 
spherical and rough [Figure 6] which could be due to CS as 
a natural polymer with less elasticity compared to synthetic 
polymer. SEM photographs showed CS nanoparticles 
adhered to mannitol particles, further optimization of freeze 
drying process may lead to free flowing nanoparticles.
Differential scanning calorimetry
Differential scanning calorimetric thermogram of pure 
drug RZT [Figure 7] showed a sharp endothermic peak 
Figure 7: Differential scanning calorimetric thermograms for 
(a) rizatriptan (RZT), (b) chitosan (CS), (c) RZT + CS physical 
mixture, and (d) RZT CS nanoparticles
d
c
b
a
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QbD study for nicotinamide polymeric nanoemulsified systems
Table 4 Results of multiple regression and ANOVA for prediction of the investigated responses
Factorsa Entrapment  
capacity (%)
Entrapment  
efficiency (%)
Particle  
size (nm)
PDI Zeta potential  
(mV)
% of drug released 
in 24 hours
Intercept 54.71 59.92 184.68 0.159 31.550 13.725
X1
Estimate 3.65 2.05 54.10 0.019 8.417 0.025
P-value 0.1161 0.0129 0.0196 0.4332 0.0092 0.9650
X2
Estimate 11.89 0.04 18.97 0.003 1.333 0.825
P-value 0.0057 0.9331 0.2068 0.9137 0.4107 0.2142
X3
Estimate 0.87 1.00 43.13 0.033 6.733 0.258
P-value 0.6376 0.0801 0.0355 0.2233 0.0171 0.6565
X4
Estimate 2.21 1.23 13.20 0.023 4.683 2.042
P-value 0.2771 0.0489 0.3454 0.3670 0.0441 0.0302
X5
Estimate 0.60 2.27 7.97 0.001 3.217 1.508
P-value 0.7439 0.0096 0.5485 0.9712 0.1050 0.0639
X6
Estimate 6.55 0.50 35.87 0.014 2.883 2.175
P-value 0.0294 0.2813 0.0561 0.5523 0.1313 0.0256
X7
Estimate 2.70 1.96 41.08 0.011 1.100 3.908
P-value 0.2040 0.0147 0.0402 0.6450 0.4889 0.0050
X8
Estimate 2.56 0.10 14.92 0.016 1.517 1.325
P-value 0.2222 0.8084 0.2961 0.5099 0.3575 0.0860
Analysis of variance
DF 8 8 8 8 8 8
SS 2,608.02 191.50 102,978.02 0.030 1,944.723 347.433
MS 326.00 23.94 12,872.30 0.004 243.090 43.429
F-ratio 9.77 13.52 7.68 0.695 10.358 13.122
Prob  F 0.0436 0.0277 0.0406 0.6982 0.0402 0.0289
R2 0.9630 0.9777 0.9534 0.6495 0.9650 0.9722
Notes: Bold values reflect significant factors that affect the corresponding response. aX1–X8 are Eudragit S100, HP- -CD, and drug loadings (mg), volumes of organic and 
aqueous phases (mL), ultrasonication time (s) and amplitude (%), and level of MgCl2 as a stabilizer (%), respectively. 
Abbreviations: ANOVA, analysis of variance; PDI, polydispersity index; DF, degree of freedom; SS, sum of squares; MS, mean of squares; F-ratio, model mean square 
divided by error mean square; Prob  F value, probability of obtaining an F-ratio as large as what is observed; R2, coefficient of multiple determination for predicted versus 
measured values.
Figure 3 Pareto charts of the main effects of variables on the investigated responses.
Notes: X1–X8 are Eudragit S100, HP- -CD and drug loadings (mg), volumes of organic and aqueous phases (mL), ultrasonication time (s) and amplitude (%), and level of 
MgCl2 as a stabilizer (%), respectively.
Abbreviations: HP- -CD, 2-hydroxypropyl- -cyclodextrin; PDI, polydispersity index.
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And	after	?	
•  The	Design	Space	is	not	the	ultimate	
goal.	The	last	part	of	the	QbD	lifecyle	
is	totally	forgotten.	
•  No	control	strategy	
•  No	continuous	quality	
management	
•  Difficulty	to	implement	on-line	
measurement	technologies	
•  Another	community:	production	&	
control	engineering	
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Conclusion	
•  The	Quality-by-Design	approach	is	more	and	more	adopted	in	
the	nano-community	mainly	in	India	and	USA.	
•  Nevertheless,	some	important	parts,	e.g.	control	strategy	&	
quality	management,	are	still	ignored.	
•  Statistical	tools	exist	but	they	are	not	always	used	correctly	à	
educational	effort	is	needed.	
•  QbD	success	relies	on	the	synergistic	relationships	between		
chemists,	physicists,	biologists,	statisticians	and	engineers.	
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1.  CiPA:	Comprehensive	in	vitro	Proarrythmia	Assay		
2.  J.	D.	Strickland,	W.	R.	Lefew,	J.	Crooks,	D.	Hall,	J.	N.	Ortenzio,	K.	Dreher,	and	T.	J.	Shafer,	“In	vitro	screening	of	metal	oxide	
nanoparticles	for	effects	on	neural	function	using	cortical	networks	on	microelectrode	arrays,”	Nanotoxicology,	vol.	10,	no.	5,	pp.	619–
628,	2016.	
Towards	a	new	Cardio/Neuro-Toxicity	Testing	Model	for	Nano-Products	
•  CiPA1:	FDA,	HESI,	CSRC,	SPS,	EMA,	Health	Canada,	Japan	NIHS,	PMDA		
•  Objective:	revise	the	current	guidelines	for	evaluating	a	pharmaceutical	drugs	
tendency	to	induce	cardiac	arrythmias	(ICH	S7B).			
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To	sum	up	…	
	
•  QbD	=	Hollistic	approach	of	drug	development	
•  From	predefinites	objectives	to	full-scale	production	
•  Risk-based	approach	
A	good	Tool	for	QbD	is	not	enough	!	
	
•  Guidance	≠	Methodology	
•  Needs	an	efficient	Collaboration	between	users	
•  Requires	a	Statistical	Background	
•  Prior	Risk	Analysis	
•  Design	of	Experiments	
•  Multivariate	Analysis	
•  Control	Theory	
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